Skip to main content
. 2018 Oct 1;42(6):3220–3230. doi: 10.3892/ijmm.2018.3903

Figure 8.

Figure 8

Fisetin reduces inflammation and expression of CXCLs in LPS-induced RAW 264.7 cells. RAW 264.7 cells were pre-treated with LPS (100 ng/ml) for 2 h, followed by treatment with fisetin (15 or 30 µM) for another 24 h. (A) Flow cytometric analysis was used to quantify CD3-expressing cells. (B) CD3 expression levels were measured using western blot analysis. (C) Reverse transcription-quantitative polymerase chain reaction analysis of pro-inflammatory cytokines as indicated. (D) CXCL-1, CXCL-2, CCL-3 and CXCR-2 expression levels were assessed using western blot analysis. Values are expressed as the mean ± standard error of the mean (n=8 in each group). ***P<0.001 vs. the Con group; +P<0.05, ++P<0.01 and +++P<0.001 vs. the LPS group. Con, control; LPS, lipopolysaccharide; CXC, chemokine (C-X-C) motif; CXCL, CXC ligand; CXCR, CXC receptor; CCL-3, chemokine (C-C motif) ligand 3; F15/30, treatment with 15/30 µm fisetin.